Expression of proteinase inhibitor-9/serpinB9 in non-small cell lung carcinoma cells and tissues

International Journal of Oncology

Volumn 36, Issue 1, 2010, Pages 275-283

  Rousalova, Ilona ^a   Krepela, Evzen ^a   Prochazka, Jan ^a   Cermak, Jan ^a   Benkova, Kamila ^a  

^a UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

Author keywords

Apoptosis; Caspase; Expression; Granzyme B; Non small cell lung carcinoma; Proteinase inhibitor 9; SerpinB9

Indexed keywords

APOPTOSIS INDUCING FACTOR; GRANZYME B; MESSENGER RNA; PROTEINASE INHIBITOR; PROTEINASE INHIBITOR 9; SERPIN B9; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER SURGERY; CANCER TISSUE; CELL PROTECTION; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TUMOR DIFFERENTIATION; UPREGULATION;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANZYMES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SERPINS;

EID: 74549202283     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000498     Document Type: Article

References (52)

1. Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83: 584-594, 2008.
2. Sprecher CA, Morgenstern KA, Mathewes S, Dahlen JR, Schrader SK, Foster DC and Kisiel W: Molecular cloning, expression, and partial characterization of two novel members of the ovalbumin family of serine proteinase inhibitors. J Biol Chem 270: 29854-29861, 1995.
3. Sun J, Bird CH, Sutton V, et al: A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes. J Biol Chem 271: 27802-27809, 1996.
4. Bird CH, Blink EJ, Hirst CE, et al: Nucleocytoplasmic distribution of the ovalbumin serpin PI-9 requires a nonconventional nuclear import pathway and the export factor Crm1. Mol Cell Biol 21: 5396-5407, 2001.
5. Cunningham TD, Jiang X and Shapiro DJ: Expression of high levels of human proteinase inhibitor 9 blocks both perforin/granzyme and Fas/Fas ligand-mediated cytotoxicity. Cell Immunol 245: 32-41, 2007.
6. Kummer JA, Micheau O, Schneider P, et al: Ectopic expression of the serine protease inhibitor PI9 modulates death receptor-mediated apoptosis. Cell Death Differ 14: 1486-1496, 2007.
7. Luo X, Budihardjo I, Zou H, Slaughter C and Wang X: Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94: 481-490, 1998.
8. Stennicke HR, Jurgensmeier JM, Shin H, et al: Pro-caspase-3 is a major physiologic target of caspase-8. J Biol Chem 273: 27084-27090, 1998.
9. Metkar SS, Wang B, Ebbs ML, Kim JH, Lee YJ, Raja SM and Froelich CJ: Granzyme B activates procaspase-3 which signals a mitochondrial amplification loop for maximal apoptosis. J Cell Biol 160: 875-885, 2003.
10. Han J, Goldstein LA, Gastman BR, Froelich CJ, Yin XM and Rabinowich H: Degradation of Mcl-1 by granzyme B: implications for Bim-mediated mitochondrial apoptotic events. J Biol Chem 279: 22020-22029, 2004.
11. Han J, Goldstein LA, Gastman BR, Rabinovitz A and Rabinowich H: Disruption of Mcl-1.Bim complex in granzyme B-mediated mitochondrial apoptosis. J Biol Chem 280: 16383-16392, 2005.
12. Herrant M, Jacquel A, Marchetti S, Belhacene N, Colosetti P, Luciano F and Auberger P: Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. Oncogene 23: 7863-7873, 2004.
13. Adrain C, Murphy BM and Martin SJ: Molecular ordering of the caspase activation cascade initiated by the cytotoxic T lymphocyte/natural killer (CTL/NK) protease granzyme B. J Biol Chem 280: 4663-4673, 2005.
14. Milhas D, Cuvillier O, Therville N, et al: Caspase-10 triggers Bid cleavage and caspase cascade activation in FasL-induced apoptosis. J Biol Chem 280: 19836-19842, 2005.
15. Yin XM: Bid, a BH3-only multi-functional molecule, is at the cross road of life and death. Gene 369: 7-19, 2006.
16. Casciola-Rosen L, Garcia-Calvo M, Bull HG, Becker JW, Hines T, Thornberry NA and Rosen A: Mouse and human granzyme B have distinct tetrapeptide specificities and abilities to recruit the Bid pathway. J Biol Chem 282: 4545-4552, 2007.
17. Cullen SP, Adrain C, Luthi AU, Duriez PJ and Martin SJ: Human and murine granzyme B exhibit divergent substrate preferences. J Cell Biol 176: 435-444, 2007.
18. Mahrus S and Craik CS: Selective chemical functional probes of granzymes A and B reveal granzyme B is a major effector of natural killer cell-mediated lysis of target cells. Chem Biol 12: 567-577, 2005.
19. Cullen SP and Martin SJ: Mechanisms of granule-dependent killing. Cell Death Differ 15: 251-262, 2008.
20. Bladergroen BA, Strik MC, Bovenschen N, et al: The granzyme B inhibitor, protease inhibitor 9, is mainly expressed by dendritic cells and at immune-privileged sites. J Immunol 166: 3218-3225, 2001.
21. Hirst CE, Buzza MS, Bird CH, et al: The intracellular granzyme B inhibitor, proteinase inhibitor 9, is up-regulated during accessory cell maturation and effector cell degranulation, and overexpression enhances CTL potency. J Immunol 170: 805-815, 2003.
22. Ida H, Nakashima T, Kedersha NL, et al: Granzyme B leakage-induced cell death: a new type of activation-induced natural killer cell death. Eur J Immunol 33: 3284-3292, 2003.
23. Classen CF, Bird PI and Debatin KM: Modulation of the granzyme B inhibitor proteinase inhibitor 9 (PI-9) by activation of lymphocytes and monocytes in vitro and by Epstein-Barr virus and bacterial infection. Clin Exp Immunol 143: 534-542, 2006.
24. Bladergroen BA, Strik MC, Wolbink AM, Wouters D, Broekhuizen R, Kummer JA and Hack CE: The granzyme B inhibitor proteinase inhibitor 9 (PI9) is expressed by human mast cells. Eur J Immunol 35: 1175-1183, 2005.
25. Buzza MS, Hirst CE, Bird CH, Hosking P, McKendrick J and Bird PI: The granzyme B inhibitor, PI-9, is present in endothelial and mesothelial cells, suggesting that it protects bystander cells during immune responses. Cell Immunol 210: 21-29, 2001.
26. Young JL, Sukhova GK, Foster D, Kisiel W, Libby P and Schonbeck U: The serpin proteinase inhibitor 9 is an endogenous inhibitor of interleukin 1beta-converting enzyme (caspase-1) activity in human vascular smooth muscle cells. J Exp Med 191: 1535-1544, 2000.
27. Bots M, de Bruin E, Rademaker-Koot MT and Medema JP: Proteinase inhibitor-9 expression is induced by maturation in dendritic cells via p38 MAP kinase. Hum Immunol 68: 959-964, 2007.
28. Buzza MS, Hosking P and Bird PI: The granzyme B inhibitor, PI-9, is differentially expressed during placental development and up-regulated in hydatidiform moles. Placenta 27: 62-69, 2006.
29. Medema JP, de Jong J, Peltenburg LT, et al: Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci USA 98: 11515-11520, 2001.
30. Oudejans JJ, Harijadi H, Kummer JA, et al: High numbers of granzyme B/CD8-positive tumour-infiltrating lymphocytes in nasopharyngeal carcinoma biopsies predict rapid fatal outcome in patients treated with curative intent. J Pathol 198: 468-475, 2002.
31. Jiang X, Patterson NM, Ling Y, Xie J, Helferich WG and Shapiro DJ: Low concentrations of the soy phytoestrogen genistein induce proteinase inhibitor 9 and block killing of breast cancer cells by immune cells. Endocrinology 149: 5366-5373, 2008.
32. van Houdt IS, Oudejans JJ, van den Eertwegh AJ, et al: Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma. Clin Cancer Res 11: 6400-6407, 2005.
33. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC (eds): Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press, Lyon, 2004.
34. Mountain CF: Revisions in the International system for staging lung cancer. Chest 11: 1710-1717, 1997.
35. -ΔΔCT method. Methods 25: 402-408, 2001.
36. Smith PK, Krohn RI, Hermanson GT, et al: Measurement of protein using bicinchoninic acid. Anal Biochem 150: 76-85, 1985.
37. Schägger H and von Jagow G: Tricine-sodium dodecylsulfate- polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem 166: 368-379, 1987.
38. Law RH, Zhang Q, McGowan S, et al: An overview of the serpin superfamily. Genome Biol 7: 216, 2006.
39. Mangan MS, Kaiserman D and Bird PI: The role of serpins in vertebrate immunity. Tissue Antigens 72: 1-10, 2008.
40. Krepela E, Prochazka J, Liu X, Fiala P and Kinkor Z: Increased expression of Apaf-1 and procaspase-3 and the functionality of intrinsic apoptosis apparatus in non-small cell lung carcinoma. Biol Chem 385: 153-168, 2004.
41. Tanaka K, Harashima N, Niiya F, et al: Serine proteinase inhibitor 9 can be recognized by cytotoxic T lymphocytes of epithelial cancer patients. Jpn J Cancer Res 93: 198-208, 2002.
42. Majima T, Ichikura T, Chochi K, et al: Exploitation of interleukin-18 by gastric cancers for their growth and evasion of host immunity. Int J Cancer 118: 388-395, 2006.
43. de Hooge AS, Berghuis D, Santos SJ, et al: Expression of cellular FLICE inhibitory protein, caspase-8, and protease inhibitor-9 in Ewing sarcoma and implications for susceptibility to cytotoxic pathways. Clin Cancer Res 13: 206-214, 2007.
44. Kannan-Thulasiraman P and Shapiro DJ: Modulators of inflammation use nuclear factor-kappa B and activator protein-1 sites to induce the caspase-1 and granzyme B inhibitor, proteinase inhibitor 9. J Biol Chem 277: 41230-41239, 2002.
45. Jiang X, Ellison SJ, Alarid ET and Shapiro DJ: Interplay between the levels of estrogen and estrogen receptor controls the level of the granzyme inhibitor, proteinase inhibitor 9 and susceptibility to immune surveillance by natural killer cells. Oncogene 26: 4106-4114, 2007.
46. Wodrich W and Volm M: Overexpression of oncoproteins in non-small cell lung carcinomas of smokers. Carcinogenesis 14: 1121-1124, 1993.
47. Szabo E, Riffe ME, Steinberg SM, Birrer MJ and Linnoila RI: Altered cJUN expression: an early event in human lung carcinogenesis. Cancer Res 56: 305-315, 1996.
48. Shimizu Y, Kinoshita I, Kikuchi J, Yamazaki K, Nishimura M, Birrer MJ and Dosaka-Akita H: Growth inhibition of non-small cell lung cancer cells by AP-1 blockade using a cJun dominant-negative mutant. Br J Cancer 98: 915-922, 2008.
49. Loeb CR, Harris JL and Craik CS: Granzyme B proteolyzes receptors important to proliferation and survival, tipping the balance towards apoptosis. J Biol Chem 281: 28326-28335, 2006.
50. Mahrus S, Kisiel W and Craik CS: Granzyme M is a regulatory protease that inactivates proteinase inhibitor 9, an endogenous inhibitor of granzyme B. J Biol Chem 279: 54275-54282, 2004.
51. Falleni M, Pellegrini C, Marchetti A, et al: Survivin gene expression in early-stage non-small cell lung cancer. J Pathol 200: 620-626, 2003.
52. Caldas H, Jaynes FO, Boyer MW, Hammond S and Altura RA: Survivin and Granzyme B-induced apoptosis, a novel anticancer therapy. Mol Cancer Ther 5: 693-703, 2006.